Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Qatar Biobank Cohort Study: Study Design and First Results.

Al Thani A, Fthenou E, Paparrodopoulos S, Al Marri A, Shi Z, Qafoud F, Afifi N.

Am J Epidemiol. 2019 Aug 1;188(8):1420-1433. doi: 10.1093/aje/kwz084.

PMID:
30927351
2.

Implementing and tailoring a western-developed communication skills training program for graduate medical trainees in Qatar.

Bylund CL, Alyafei K, Anand A, Al Marri A, Omer W, Sinha T, Alam W, Abdelrahim H, Al-Khal A.

Int J Med Educ. 2017 Jan 14;8:16-18. doi: 10.5116/ijme.5856.72b4. No abstract available.

3.

The Qatar Biobank: background and methods.

Al Kuwari H, Al Thani A, Al Marri A, Al Kaabi A, Abderrahim H, Afifi N, Qafoud F, Chan Q, Tzoulaki I, Downey P, Ward H, Murphy N, Riboli E, Elliott P.

BMC Public Health. 2015 Dec 3;15:1208. doi: 10.1186/s12889-015-2522-7.

4.

Serotype-conversion in Shigella flexneri: identification of a novel bacteriophage, Sf101, from a serotype 7a strain.

Jakhetia R, Marri A, Ståhle J, Widmalm G, Verma NK.

BMC Genomics. 2014 Aug 30;15:742. doi: 10.1186/1471-2164-15-742.

5.

Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment.

Derbala M, Rizk N, Al-Kaabi S, Amer A, Shebl F, Al Marri A, Aigha I, Alyaesi D, Mohamed H, Aman H, Basem N.

J Viral Hepat. 2009 Oct;16(10):689-96. doi: 10.1111/j.1365-2893.2009.01096.x. Epub 2009 Mar 25.

PMID:
19486470
6.

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2006 Dec;80(24):12149-59. Epub 2006 Oct 11.

7.

PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons.

Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, Williams BR, Silverman RH, Gale M Jr, Diamond MS.

J Virol. 2006 Jul;80(14):7009-19.

8.

Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms.

Chung KM, Nybakken GE, Thompson BS, Engle MJ, Marri A, Fremont DH, Diamond MS.

J Virol. 2006 Feb;80(3):1340-51.

9.

Complement activation is required for induction of a protective antibody response against West Nile virus infection.

Mehlhop E, Whitby K, Oliphant T, Marri A, Engle M, Diamond MS.

J Virol. 2005 Jun;79(12):7466-77.

10.

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.

Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS.

Nat Med. 2005 May;11(5):522-30. Epub 2005 Apr 24.

11.

Supplemental Content

Support Center